OSR Holdings Inc. announced that its subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG regarding a proposed global exclusive license for VXM01, Vaximm's lead immunotherapy candidate. The term sheet outlines a structure in which BCM Europe would establish an investment vehicle, BCM DecentralizedScience Investors I, LP, to act as the licensee. Under the proposed terms, the agreement would include a $30 million upfront payment and up to $815 million in potential milestone payments. The transaction is subject to further review by Vaximm's Board of Directors, an independent third-party valuation, final documentation, and necessary approvals. No definitive agreement has been signed at this stage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN60952) on January 12, 2026, and is solely responsible for the information contained therein.